Page 126 - 《中国药房》2025年9期

A. Current therapy of the patients with MDS：walking to‐ world experience with luspatercept and predictors of re‐
wards personalized therapy[J]. J Clin Med，2021，10（10）： sponse in myelodysplastic syndromes with ring sidero‐
2107. blasts[J]. Am J Hematol，2022，97（6）：E210-E214.
[ 8 ] HATZIMICHAEL E，TIMOTHEATOU D，KOUMPIS E， [18] LANINO L，RESTUCCIA F，PEREGO A，et al. Real-
et al. Luspatercept：a new tool for the treatment of anemia world efficacy and safety of luspatercept and predictive
related to β-thalassemia，myelodysplastic syndromes and factors of response in patients with lower risk myelodys‐
primary myelofibrosis[J]. Diseases，2022，10（4）：85. plastic syndromes with ring sideroblasts[J]. Am J Hema‐
[ 9 ] SCHMIERER B，HILL C S. TGF-β-SMAD signal trans‐ tol，2023，98（8）：E204-E208.
duction：molecular specificity and functional flexibility[J]. [19] KOONS M，SIGNORELLI J R，BELL C，et al. Real-
Nat Rev Mol Cell Biol，2007，8（12）：970-982. world practices of luspatercept at an academic medical
[10] FENAUX P，HAASE D，SANTINI V，et al. Myelodys‐ center[J]. J Oncol Pharm Pract，2024，30（7）：1173-1180.
plastic syndromes：ESMO clinical practice guidelines for [20] GONG Y，HE G. Topic：As08-treatment/AS08i-
diagnosis，treatment and follow-up [J]. Ann Oncol，2021， observational studies：real world data confirms activity of
32（2）：142-156. luspatercept in higher risk and hypomethylating agents-
[11] LOCATELLI F，THOMPSON A A，KWIATKOWSKI J L， failed patients with myelodysplastic syndromes[J]. Leuk
et al. Betibeglogene autotemcel gene therapy for non-β /β Res，2023，128：107275.
0
0
genotype β-thalassemia[J]. N Engl J Med，2022，386（5）： [21] MUKHERJEE S，BROWN-BICKERSTAFF C，MCBRIDE
415-427. A，et al. Real-world outcomes of patients with lower-risk
[12] HIGGINS J P T，THOMPSON S G，DEEKS J J，et al. myelodysplastic syndromes （LR-MDS） treated with
Measuring inconsistency in meta-analyses[J]. BMJ，2003， luspatercept：an evaluation of US clinical practice utiliza‐
327（7414）：557-560. tion and treatment patterns[J]. Blood，2022，140（Suppl.
[13] PLATZBECKER U，GERMING U，GÖTZE K S，et al. 1）：944-946.
Luspatercept for the treatment of anaemia in patients with [22] KOMROKJI R S，AL ALI N，BALL S，et al. Luspatercept
lower-risk myelodysplastic syndromes （PACE-MDS）：a for treatment of lower risk myelodysplastic syndromes：
multicentre，open-label phase 2 dose-finding study with real world data replicates medalist study results and con‐
long-term extension study[J]. Lancet Oncol，2017，18 firms activity among hypomethylating agents and
（10）：1338-1347. lenalidomide-treated patients[J]. Blood，2022，140（Suppl.
[14] FENAUX P，PLATZBECKER U，MUFTI G J，et al. 1）：4039-4041.
Luspatercept in patients with lower-risk myelodysplastic [23] KOMROKJI R S，AGUIRRE L E，AL ALI N H，et al. Ac‐
syndromes[J]. N Engl J Med，2020，382（2）：140-151. tivity of luspatercept and ESAs combination for treatment
[15] PLATZBECKER U，DELLA PORTA M G，SANTINI V， of anemia in lower-risk myelodysplastic syndromes[J].
et al. Efficacy and safety of luspatercept versus epoetin Blood Adv，2023，7（14）：3677-3679.
alfa in erythropoiesis-stimulating agent-naive，transfusion- [24] MALCOVATI L，STEVENSON K，PAPAEMMANUIL E，
dependent，lower-risk myelodysplastic syndromes et al. SF3B1-mutant MDS as a distinct disease subtype：a
（COMMANDS）：interim analysis of a phase 3，open- proposal from the International Working Group for the
label，randomised controlled trial[J]. Lancet，2023，402 Prognosis of MDS[J]. Blood，2020，136（2）：157-170.
（10399）：373-385. [25] GARZA A D L，CAMERON R C，GUPTA V，et al. The
[16] ZHANG Z X，HU Q L，TANG X D，et al. Treatment of splicing factor Sf3b1 regulates erythroid maturation and
refractory or relapsed myelodysplastic neoplasms with proliferation via TGF- β signaling in zebrafish[J]. Blood
luspatercept：a multicenter Chinese study[J]. Ann Hematol， Adv，2019，3（14）：2093-2104.
2023，102（11）：3039-3047. （收稿日期：2024-10-29 修回日期：2025-02-20）
[17] FARRUKH F，CHETRAM D，AL-KALI A，et al. Real- （编辑：刘明伟）

· 1140 · China Pharmacy 2025 Vol. 36 No. 9 中国药房 2025年第36卷第9期